Meta-Regression of Hepatitis C Virus Infection in Relation to Time Since Onset of Illicit Drug Injection: The Influence of Time and Place
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The authors examined the relation between time since onset of illicit drug injection (time at risk) and rates of hepatitis C virus (HCV) infection by using meta-regression. In 72 prevalence studies, median time since onset of injection was 7.24 years and median prevalence was 66.02%. The model showed statistically significant linear and quadratic effects of time at risk on HCV prevalence and significantly higher prevalence in developing and transitional countries and in earlier samples (1985-1995). In developed countries post-1995, mean fitted prevalence was 32.02% (95% confidence interval: 25.31, 39.58) at 1 year of injection and 53.01% (95% confidence interval: 40.69, 65.09) at 5 years. In developing/transitional countries post-1995, mean fitted HCV prevalence was 59.13% (95% confidence interval: 30.39, 82.74) at 1 year of injection. In 10 incidence studies, median time at risk was 5.29 years and median cumulative HCV incidence was 20.69%. Mean fitted cumulative incidence was 27.63% (95% confidence interval: 16.92, 41.70) at 1 year of drug injection. The authors concluded that time to HCV infection in developed countries has lengthened. More rapid onset of HCV infection in drug injectors in developing/transitional countries resembles an earlier era of the HCV epidemic in other regions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Experimental Design and Data Analysis for Biologists
Quinn, G. P., & Keough, M. J. (2002) · doi:10.1017/cbo9780511806384 · Cited by 10,674 · cited 1×
“Since the analysis included samples of only those individuals who had injected drugs, the intercept term should not be interpreted as the average HCV rate among unexposed persons (25).”
BackgroundFunnel plots for detecting bias in meta-analysis
Sterne, J. A. C., & Egger, M. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00377-8 · Cited by 3,779
Methods for Trend Estimation from Summarized Dose-Response Data, with Applications to Meta-Analysis
Greenland, S., & Longnecker, M. P. (1992) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a116237 · Cited by 2,353 · cited 1×
“Methods requiring more than 2 categories per study would have reduced our sample by 25% for prevalence studies and 50% for incidence studies (24).”
BackgroundDes Jarlais, D. C., Perlis, T., Arasteh, K., Torian, L. V., Hagan, H., Beatrice, S., Smith, L., Wethers, J., Milliken, J., Mildvan, D., et al. (2005) · AIDS · doi:10.1097/01.aids.0000192066.86410.8c · Cited by 163 · cited 2×
“Des Jarlais, 2005, study 2 (15) New York 2000–2001 Drug treatment 8.”
BackgroundSelf-citation
Cited by
EASL Recommendations on Treatment of Hepatitis C 2018
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.026 · Cited by 2,827
Nelson, P. K., Mathers, B. M., Cowie, B., Hagan, H., Des Jarlais, D., Horyniak, D., & Degenhardt, L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61097-0 · Cited by 1,267
Self-citationEASL recommendations on treatment of hepatitis C: Final update of the series☆
Pawlotsky, J.-M., Negro, F., Aghemo, A., Berenguer, M., Dalgard, O., Dusheiko, G., Marra, F., Puoti, M., & Wedemeyer, H. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.018 · Cited by 1,252
EASL Recommendations on Treatment of Hepatitis C 2015
(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.03.025 · Cited by 1,156
EASL Recommendations on Treatment of Hepatitis C 2016
(2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.09.001 · Cited by 985
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
(2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.003 · Cited by 855
Zibbell, J. E., Asher, A. K., Patel, R. C., Kupronis, B., Iqbal, K., Ward, J. W., & Holtzman, D. (2018) · American Journal of Public Health · doi:10.2105/ajph.2017.304132 · Cited by 698
Public health and international drug policy
Csete, J., Kamarulzaman, A., Kazatchkine, M., Altice, F., Balicki, M., Buxton, J., Cepeda, J., Comfort, M., Goosby, E., Goulão, J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00619-x · Cited by 641
Medication-Assisted Treatment of Opioid Use Disorder: Review of the Evidence and Future Directions
Connery, H. S. (2015) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000075 · Cited by 576
Osburn, W. O., Fisher, B. E., Dowd, K. A., Urban, G., Liu, L., Ray, S. C., Thomas, D. L., & Cox, A. L. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.09.017 · Cited by 360
Levitsky, J., Formica, R. N., Bloom, R. D., Charlton, M., Curry, M., Friedewald, J., Friedman, J., Goldberg, D., Hall, S., Ison, M., et al. (2017) · American Journal of Transplantation · doi:10.1111/ajt.14381 · Cited by 327
Hagan, H., Pouget, E. R., & Des Jarlais, D. C. (2011) · Journal of Infectious Diseases · doi:10.1093/infdis/jir196 · Cited by 313
Self-citationLarney, S., Kopinski, H., Beckwith, C. G., Zaller, N. D., Jarlais, D. D., Hagan, H., Rich, J. D., van den Bergh, B. J., & Degenhardt, L. (2013) · Hepatology · doi:10.1002/hep.26387 · Cited by 314
Self-citationTurner, K. M. E., Hutchinson, S., Vickerman, P., Hope, V., Craine, N., Palmateer, N., May, M., Taylor, A., De Angelis, D., Cameron, S., et al. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03515.x · Cited by 299
Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C
(2010) · National Academies Press eBooks · doi:10.17226/12793 · Cited by 245
“Most of the estimates of HCV incidence rates in IDUs in the United States have been between 15-30 per 100 person years at risk, with higher incidence found in recent-onset injectors (Garfein et al., 1998; Hagan et al., 2008; Hagan et al., 2001; Hahn et al., 2002; Maher et al., 2006; Smyth et al., 2000; Thorpe et al.,…”
BackgroundInstitute of Medicine Recommendations for the Prevention and Control of Hepatitis B and C
Mitchell, A. E., Colvin, H. M., & Beasley, P. R. (2010) · Hepatology · doi:10.1002/hep.23561 · Cited by 195
Recommendations for the management of hepatitis C virus infection among people who inject drugs
Grebely, J., Robaeys, G., Bruggmann, P., Aghemo, A., Backmund, M., Bruneau, J., Byrne, J., Dalgard, O., Feld, J. J., Hellard, M., et al. (2015) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2015.07.005 · Cited by 194
“Studies on time to HCV infection have demonstrated highest incidence in the initial years of injecting (Hagan et al., 2008; Roy, Boudreau, & Boivin, 2009).”
BackgroundInfluentialGrebely, J., Dore, G. J., Morin, S., Rockstroh, J. K., & Klein, M. B. (2017) · Journal of the International AIDS Society · doi:10.7448/ias.20.1.22146 · Cited by 171
“7 million new HCV infections globally, with 23% attributable to current injecting drug use [19], related to the high HCV incidence among PWID in many settings [3–6], particularly in the initial years of injecting [5,21].”
Background
Metadata
- Authors
- Hagan, H., Pouget, E. R., Des Jarlais, D. C., & Lelutiu-Weinberger, C.
- Venue
- American Journal of Epidemiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-10-09
- Volume
- 168
- Issue
- 10
- Pages
- 1099-1109
- ISSN
- 0002-9262 (ISSN-L)
- 1476-6256
- OpenAlex
- W2153750363
- Cited by
- 222
- References
- 4
- FWCI
- 4.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.